RxDoctor Payments Data

Daniel Hynes, MD

Internal Medicine · Winchester, VANPI 1902248826

Payments from drug & device makers

$1,785in general payments, 2019–2025

Across 35 payments — averaging $50.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$426
  • AstraZeneca$415
  • Bayer$213
  • GSK$181
  • Pulmonx Corporation$126
  • Sanofi$92
  • plus $331 from 7 others

What the payments were for

  • Consulting fees$20011%
  • Travel & lodging$37821%
  • Food & beverage$1,12763%
  • Education$804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,785 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$153,612
Medicare patients
620
Services billed
1,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate44$592,845
Trelegy ElliptaFluticasone/Umeclidin/Vilanter449$353,444
Prolastin CAlpha-1-Proteinase Inhibitor19$217,000
NucalaMepolizumab20$96,444
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr122$56,813
Breo ElliptaFluticasone/Vilanterol123$53,448
Breztri AerosphereBudesonide/Glycopyr/Formoterol59$48,292
Stiolto RespimatTiotropium Br/Olodaterol Hcl77$41,302
Spiriva RespimatTiotropium Bromide47$26,237
SymbicortBudesonide/Formoterol Fumarate73$22,263
Combivent RespimatIpratropium/Albuterol Sulfate32$17,958
Incruse ElliptaUmeclidinium Bromide52$17,910
Advair HfaFluticasone Propion/Salmeterol32$15,527
EliquisApixaban20$14,174
Roflumilast78$9,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$181$583,269781 claims
AstraZenecaBreztri Aerosphere, Symbicort$415$70,556132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →